May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAdamowicz, Jan-
Autor(es): dc.creatorJuszczak, Kajetan-
Autor(es): dc.creatorDrewa, Tomasz-
Data de aceite: dc.date.accessioned2026-02-09T12:20:52Z-
Data de disponibilização: dc.date.available2026-02-09T12:20:52Z-
Data de envio: dc.date.issued2020-05-28-
Data de envio: dc.date.issued2020-05-28-
Data de envio: dc.date.issued2020-07-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41262-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/abs/pii/S0306987720305909-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1159464-
Descrição: dc.descriptionCOVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceMedical Hypotheses-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subject5-alpha-reductase inhibitors-
Título: dc.titleMay patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.